Introduction
The widespread use of fluoroquinolone agents has been associated with the recent emergence of quinolone resistance in various bacterial species, particularly in Staphylococcus aureus. Although S. aureus was originally susceptible to almost all quinolones, highly resistant isolates are now prevalent. [1] [2] [3] Several mechanisms are responsible for quinolone resistance, including: point mutations in the gyrA 4 and gyrB 5 genes, which encode the subunits of DNA gyrase; 6 analogous mutations in grlA, 7 which encodes one component of DNA topoisomerase IV; and a mechanism involving the norA gene, which encodes a drug efflux pump. 8 Of these mechanisms, mutations in gyrA are thought to be the most important for the acquisition of resistance. DNA gyrase is a target enzyme of quinolone agents and is composed of two GyrA and two GyrB subunits. Substitution of Ser85, Glu88 or, especially, Ser84 in S. aureus GyrA has been shown to lead to quinolone resistance. [9] [10] [11] [12] [13] [14] Substitution of Asp437 or Arg458 in GyrB of S. aureus can result in quinolone resistance. 5 Replacement of the former residue is thought to be more important for the acquisition of resistance than replacement of the latter, since substitutions of Asp437 are more common than those of Arg458 and are associated with a higher level of resistance. Quinolone resistance associated with mutation of the residue corresponding to Asp437 in GyrB of S. aureus has also been demonstrated for GyrB of Escherichia coli, 15 Neisseria gonorrhoeae, 16 Mycobacterium tuberculosis 17 and Streptococcus pneumoniae. 18 Furthermore, the type and site of mutations as well as the amino acid sequence surrounding mutated residues are highly conserved for both GyrA and GyrB among a variety of bacterial species. mutations in S. aureus. 7, [30] [31] Recently, GrlB mutations related to quinolone resistance have been reported in E. coli 32 and S. pneumoniae; 33 the mutation described in the latter was Asp435, which corresponds to Asp437 of GyrB in S. aureus. However no such mutation in GrlB has been reported in S. aureus.
We examined the distribution of gyrA, gyrB, grlA and grlB mutations in 110 clinical isolates of S. aureus in order to assess how widespread they are and to determine their relationship with quinolone resistance.
Materials and methods

Bacteria
One hundred and ten clinical isolates of S. aureus collected in 1992 from patients in five general hospitals in Japan were used in this study. These were chosen from a total of 292 isolates so as to include isolates with various degrees of susceptibility and resistance to ofloxacin.
Antimicrobial agents and MIC determinations
Ofloxacin and levofloxacin were from Daiichi Pharmaceutical Co. Ltd (Tokyo, Japan), tosufloxacin and pazuflo x acin from Toyama Chemical Co., Ltd (Tokyo, Japan), ciprofloxacin from Bayer Yakuhin Ltd (Osaka, Japan), temafloxacin from Tanabe Seiyaku Co. Ltd (Osaka, Japan), sparfloxacin from Dainippon Pharmaceutical Co.
Ltd (Okaka, Japan), prulifloxacin from Meiji Seika Kaisha, Ltd (Tokyo, Japan) and balofloxacin from Chugai Pharmaceutical Co. Ltd (Tokyo, Japan). The MICs of each agent were determined by a standard broth microdilution method.
Primers for PCR and DNA sequencing
Mutations in gyrA, gyrB, grlA and grlB were detected by polymerase chain reaction (PCR) and DNA sequencing using the oligonucleotide primers shown in Table I . Primers 1 and 2 have been described previously, 4,9 while the remaining 15 primers were designed for this study.
Detection of GyrA Ser84 mutations
Point mutation at Ser84 of GyrA was detected by restriction fragment length polymorphism (RFLP) analysis of PCR products. 4, 9 The region of gyrA encompassing the Ser84 codon was amplified by PCR, the PCR products were digested with HinfI and the resulting DNA fragments were examined by agarose gel electrophoresis. The Ser84 codon corresponds to a HinfI restriction site, which is lost as a result of mutation at this codon, thus allowing mutant and non-mutant isolates to be identified on the basis of band pattern on electrophoresis. PCR was performed in 100 L of reaction mixture containing DNA extract (1 g), 200 M of each deoxynucleoside triphosphate, 0.5 M each of primers, 2.5 U of Taq DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA), 50 mM KCl, 10 mM Tris-HC1 (pH 8.3), 1.5 mM MgCl 2 and 0.01% gelatin. Twenty-five cycles were performed for each reaction, with each cycle consisting of 30 s at 94°C (denaturation), 30 s at 55°C (annealing) and 2 min at 72°C (primer extention). PCR conditions, except for annealing temperature and number of cycles, were constant throughout the study.
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Detection of GyrB Asp437 mutations
The Asp437 codon of gyrB also corresponds to a HinfI restriction site. Mutations at this codon were therefore also detected by PCR and RFLP analysis with HinfI, as for detection of GyrA Ser84 mutations. PCR was performed for 25 cycles with an annealing temperature of 52°C.
Detection of GrlB Asp432 and GrlA Ser80 mutations
Although grlB mutations responsible for fluoroquinolone resistance have not been described in S. aureus, a likely site of such mutations, should they exist, would be the codon for Asp432, which is equivalent to the Asp437 codon of GyrB. Since grlB and grlA are adjacent on the S. aureus chromosome, mutations in grlB Asp432 and grlA Ser80 codons, both of which correspond to HinfI sites, were detected at the same time by RFLP analysis with HinfI of PCR products encompassing both genes. Fragments of 932, 229 and 148 bp are indicative of non-mutant isolates, fragments of 1161 and 148 bp indicate a mutation at Asp432 of GrlB, fragments of 1080 and 229 bp reflect a mutation at Ser80 of GrlA, and a single 1309 bp fragment indicates a double mutant. PCR was performed for 30 cycles with an annealing temperature of 51°C.
Nucleotide sequence determination
Nucleotide sequences of PCR products were determined in order to identify specific point mutations, to detect multiple mutations, and to confirm the accuracy of PCR and RFLP analysis. When mutations not described previously were observed, results were confirmed by sequencing the complementary DNA strand. A sequencing template was produced by an asymmetrical second PCR, which was performed with internal primer pairs and the first PCR products. First PCR was newly performed with 30 cycles for gyrB (reverse) by RB1 and primer 2 with annealing at 55°C. Asymmetrical PCR was performed with 40 cycles with different conditions as follows; gyrA, 0.02 M RA3 and 0.75 M RA4, annealing at 55°C; gyrB, 0.02 M RB3 and 0.75 M RB4, annealing at 52°C; grlB-grlA, 0.02 M LB3 and 0.75 M LA4, annealing at 51°C; gyrB (reverse), 0.5 M RB3 and 0.02 M RA4, annealing at 55°C; grlB (reverse), 0.5 M LB3 and 0.02 M LA4, annealing at 51°C.
Nucleotide sequencing was performed with a Sequenase version 2.0 DNA Sequencing Kit (Biochemical, Cleveland, 
Results
Distribution of the GyrA Ser84 mutation
Seventy-one of the 110 isolates (70%) had mutations at Ser84 of GyrA. Mutant and non-mutant isolates were clearly separated by ofloxacin MIC, with a border zone of 4-8 mg/L; no susceptible isolates with mutations or highly resistant isolates without mutations were observed ( Figure  1) .
The distributions of mutant isolates on the basis of MICs of other quinolone agents were also examined. A clear separation of mutant and non-mutant isolates was obtained for each agent. Furthermore, drugs with lower median MICs (MIC 50 ) tended to have lower border zone MICs for separation of mutant from non-mutant isolates.
Distribution of the GrlA Ser80 mutation
Seventy-seven of the 110 isolates (70%) were identified as GrlA Ser80 mutants. For ofloxacin, the border zone MICs of mutant and non-mutants were 0.5-32 mg/L (Figure 2) .
Generally, the distributions of mutant isolates according to MICs of various quinolone agents differed from those for GyrA Ser84 mutants. Although GrlA Ser80 mutants tended to be distributed toward the higher end of the MIC range, relatively highly resistant isolates without the Ser80 mutation were also observed. Hence, mutant and nonmutant isolates were not clearly separated by a distinct border zone. Several mutant isolates were highly susceptible to sparfloxacin and tosufloxacin.
Occurrence of GyrB Asp437 and GrlB Asp432 mutations
None of the 100 isolates contained mutations at Asp437 of GyrB, and only one GrlB Asp432 mutant was detected. This latter isolate also had mutations at GyrA Ser84 and GrlA Ser80, and had an ofloxacin MIC of 16 mg/L.
Relationship between GrlA and GyrA mutations
With regard to GyrA Ser84 and GrlA Ser80, 26 isolates were classified as non-mutant, 64 as grlA and gyrA double mutants, 13 as grlA single mutants and seven as gyrA single mutants. Their distributions according to ofloxacin MICs were compared (Figure 3 ). Since the range of MICs for grlA mutants was broader than that for gyrA mutants, nonmutant isolates were largely restricted to the susceptible zone and double mutant isolates to the resistant zone. GrlA single mutant strains were restricted to an intermediate zone and gyrA single mutants were detected in a zone of moderate resistance.
Characterization of point mutations
The nucleotide sequences surrounding the site of mutation of gyrA, gyrB, grlA and grlB were determined for selected isolates. Of the 12 isolates highly resistant to ofloxacin (MIC 64 mg/L), all contained Ser84 Leu mutations in GyrA, eight also contained Glu88 Lys mutations and two others contained Ser85 Pro mutations (Table II) . All 12 isolates contained Ser80 Phe and Glu84 Lys mutations in GrlA, but only two had mutations in gyrB; the Pro456 Ser mutation has not been described previously. No mutations in grlB were detected in any of these 12 isolates.
Several isolates with low (borderline) or intermediate resistance to ofloxacin and which were classified as GyrA Ser84 or GrlA Ser80 mutants were subjected to nucleotide sequencing of their respective genes, and sequences were compared with those of highly resistant strains (Figure 4 mutations were detected and, in contrast with gyrA, double mutants were present among isolates with low and intermediate resistance. Mutation of Ser Tyr80 was less frequent and tended to be associated with lower resistance than the mutation to Phe. For the one strain shown to have a GrlB Asp432 (GAT) mutation by RFLP analysis, sequencing revealed the mutant residue to be Val (GTT).
The grlA sequences of the seven isolates found to be gyrA single mutants by RFLP analysis were also determined; all were confirmed not to have mutations at Ser80, but they all contained Glu Lys84 mutations.
The three isolates with ofloxacin MICs of 4 or 8 mg/L and found to be both grlA and gyrA non-mutants on RFLP analysis were also subjected to nucleotide sequencing. All were confirmed to be non-mutant with regard to these two genes. All sequence determinations were thus consistent with the RFLP patterns for PCR products.
Discussion
Our findings confirm that mutations in gyrA and grlA are both important determinants of quinolone resistance in S. aureus, since they were widely distributed among 110 clinical isolates and were present in all isolates with high or Figure 1 .
moderate levels of resistance. All GyrA Ser84 mutant isolates detected in the present study also had mutations at Ser80 or Glu84 of GrlA. These observations are consistent with the suggestions of Ferrero et al. 7 that GrlA is the primary target of quinolone agents in S. aureus, and that gyrA mutations are always preceded by grlA mutations.
GyrA Ser84 mutant and non-mutant isolates exhibited distinct distributions of MICs of each quinolone drug tested. This clear separation of clinical isolates, regardless of their various genetic backgrounds, indicates the importance of this mutation in the acquisition of quinolone resistance. The distributions of GrlA Ser80 mutant and non-mutant isolates were not as clearly separated with the various drugs; thus, several mutants were highly susceptible to sparfloxacin and tosufloxacin, suggesting that this grlA mutation alone is not sufficient for drug resistance.
Few gyrB mutants were detected in the present study, which contrasts with previous studies performed mainly on in-vitro generated strains. 5, 15 , Thus, gyrB mutations may not be stable in the clinical environment. 34 Only those isolates highly resistant to ofloxacin contained two point mutations in gyrA, and gyrA mutants of low or intermediate resistance were Ser84 single mutants. The acquisition of two point mutations in gyrA appears to be important for a high level of quinolone resistance. In contrast, double mutations in grlA were detected in isolates of various levels of resistance, indicating that the existence of two point mutations in grlA is not closely related to a high level of quinolone resistance. The types and positions of the mutations detected in the present study were limited to only a few patterns. Previous studies of various bacterial species [19] [20] [21] [22] [23] [24] [25] [26] also revealed that GyrA or GrlA mutations responsible for quinolone resistance are restricted to only one or two point mutations at limited positions. It is not clear why strains with more than three point mutations in these genes have not been detected. However, while the occurrence of additional mutations may prove beneficial for bacteria by reducing the affinity of the corresponding enzymes for quinolone agents, it may also result in reduced enzymatic activity and consequent decline in bacterial growth and survival.
We also detected mutations in gyrB and grlB that have not been previously described. Both of these mutations may be related to quinolone resistance; the Pro456 Ser mutation in GyrB was detected in two of the 12 isolates with the highest resistance to ofloxacin, whereas the Asp432 Val mutation in GrlB is located at a position analogous to Asp437 mutations in GyrB, and moreover, Asp435 mutation in GrlB of S. pneumoniae. Overall, however, these findings do not suggest that mutations in gyrB or grlB are closely related to a high level of quinolone resistance.
Strains of S. aureus highly resistant to quinolones (MIC 512 mg/L) without mutations in gyrA have been produced by artificial induction of resistance in vitro. 35 However, in the present study, the highest ofloxacin MIC for gyrA and grlA non-mutant isolates was 8 mg/L. A high level of resistance in clinical isolates of S. aureus may not usually depend on a single dominant factor, but may instead be produced by combinations of mutations in gyrA and grlA as well as other resistance factors, such as norA. 
